SCHEMBL1171209

SCHEMBL1171209

CC(C)OC1CCC1CN1CC[C@@]2(C[C@@H]1C)CN(C)S(=O)(=O)N2c1cc(F)cnc1C#N

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 17/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171211 0.91 BACE1 (0.35) BACE1
SCHEMBL1171128 0.89 BACE1 (0.44) BACE1
SCHEMBL1171126 0.80 BACE1 (0.37) BACE1
SCHEMBL1171069 0.79 BACE1 (0.68) BACE1
SCHEMBL1171075 0.72 BACE1 (0.60) BACE1
SCHEMBL1170511 0.66 BACE1 (0.73) BACE1
SCHEMBL1170896 0.63 BACE1 (0.71) BACE1
SCHEMBL1170646 0.61 BACE1 (0.77) BACE1
SCHEMBL1170491 0.60 BACE1 (0.62) BACE1
SCHEMBL4314859 0.60 BACE1 (1.00) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300484-B1 NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PFIZER (US) 2011-12-14 EP disclosed
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases PFIZER, INC. 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases SNCA, PARK7, HTT BACE1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.